Efficacy And SafetyADG126 in combination with pembrolizumab remains well tolerated, with no dose-limiting toxicities and no dose discontinuations in the higher dosage cohort.

Regulatory OutlookKey opinion leaders believe a drug that delivers a high response rate and maintains repeat dosing and durable efficacy in a high percentage of patients is likely to get FDA approval, potentially via an Accelerated Approval pathway.

Therapeutic PotentialPositive data from the ongoing Phase 1/2 study with ADG126 presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium solidifies its therapeutic potential in metastatic microsatellite stable colorectal cancer.

Bears Say

Market OpportunityAnalyst notes that the target population for the treatment is relatively small and there are challenges with diagnosing peritoneal metastasis, which further complicate the treatment paradigm.

Regulatory UncertaintyRegulatory uncertainty is a concern as another company is testing a similar immunotherapy combination for a similar treatment.

Safety ConcernsThree patients have discontinued treatment in the 10 mg/kg Q3W cohort, indicating potential issues with the treatment regimen.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

0.02%

Mutual Funds

11.50% Other Institutional Investors

88.48% Public Companies and

Individual Investors

Detailed Ownership Overview >

ADAG FAQ

What was Adagene’s price range in the past 12 months?

Adagene lowest stock price was $1.32 and its highest was $3.58 in the past 12 months.

What is Adagene’s market cap?

Adagene’s market cap is $89.98M.

When is Adagene’s upcoming earnings report date?

Adagene’s upcoming earnings report date is Aug 27, 2025 which is in 43 days.

How were Adagene’s earnings last quarter?

Adagene released its earnings results on Mar 24, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.33 by $0.04.

Is Adagene overvalued?

According to Wall Street analysts Adagene’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Adagene pay dividends?

Adagene does not currently pay dividends.

What is Adagene’s EPS estimate?

Adagene’s EPS estimate is -0.34.

How many shares outstanding does Adagene have?

Adagene has 47,109,554 shares outstanding.

What happened to Adagene’s price movement after its last earnings report?

Adagene reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.33. Following the earnings report the stock price went up 5.357%.

Which hedge fund is a major shareholder of Adagene?

Currently, no hedge funds are holding shares in ADAG

Adagene Stock Smart Score

Underperform

Fundamentals

Return on Equity

-55.14%

Trailing 12-Months

Asset Growth

-22.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Adagene

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.